Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Evaluation of Hematologic Endpoints Used To Assess Erythropoiesis-Stimulating Agents (ESAs): A Pooled Analysis of Data from over 10,000 Patients (pts) with Chemotherapy-Induced Anemia (CIA).

John Glaspy, David H. Henry, Jean-Luc Canon, Hung Lam, Tom Lillie

Blood (2006) 108 (11): 3764.

https://doi.org/10.1182/blood.V108.11.3764.3764

Published: 2006

Journal Articles

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

Lee Schwartzberg, MD, Timothy Rearden, MD, Lorrin Yee, MD, Barry Mirtsching, MD, Veena Charu, MD, Hung Lam, PhD, Tom Lillie, MD/PhD, Ronald Burkes, MD, Peter Silberstein, MD

Blood (2006) 108 (11): 1306.

https://doi.org/10.1182/blood.V108.11.1306.1306

Published: 2006

Journal Articles

Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.

David H. Gordon, MD, Gwen Nichols, MD, Ali Ben-Jacob, MD, Hung Lam, PhD, Tom Lillie, MD, PhD, Carole Miller, MD

Blood (2006) 108 (11): 1304.

https://doi.org/10.1182/blood.V108.11.1304.1304

Published: 2006

Journal Articles

Effect of Dose Reductions on Response to 500-μg Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.

Jean-Luc Canon, MD, Johan Vansteenkiste, MD, Gyorgy Bodoky, MD, Ma Victoria Mateos, MD, Laurent Bastit, MD, Irene Ferreira, PhD, Tom Lillie, MD

Blood (2005) 106 (11): 3558.

https://doi.org/10.1182/blood.V106.11.3558.3558

Published: 2005

Journal Articles

Effects of Dose Adjustment Rules on Safety during Erythropoietic Therapy: A Retrospective Analysis of Darbepoetin alfa Administered Either Every 3 Weeks or Weekly.

Michael Hedenus, Jean-Luc Canon, Dusan Kotasek, Tom Lillie, Lisa Hendricks, Bin Yao, Johan Vansteenkiste

Blood (2005) 106 (11): 3376.

https://doi.org/10.1182/blood.V106.11.3376.3376

Published: 2005

Journal Articles

Impact of Darbepoetin Alfa on Transfusion, Hemoglobin Response, and Survival in Cancer Patients with Chemotherapy-Induced Anemia: Results of a Meta-Analysis of Randomized, Placebo-Controlled Trials.

Nick Freemantle, Bin Yao, Melanie Calvert, Tom Lillie

Blood (2005) 106 (11): 3116.

https://doi.org/10.1182/blood.V106.11.3116.3116

Published: 2005

NARROW

Evaluation of Hematologic Endpoints Used To Assess Erythropoiesis-Stimulating Agents (ESAs): A Pooled Analysis of Data from over 10,000 Patients (pts) with Chemotherapy-Induced Anemia (CIA).

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.

Effect of Dose Reductions on Response to 500-μg Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.

Effects of Dose Adjustment Rules on Safety during Erythropoietic Therapy: A Retrospective Analysis of Darbepoetin alfa Administered Either Every 3 Weeks or Weekly.

Impact of Darbepoetin Alfa on Transfusion, Hemoglobin Response, and Survival in Cancer Patients with Chemotherapy-Induced Anemia: Results of a Meta-Analysis of Randomized, Placebo-Controlled Trials.

Email alerts

ASH Publications

American Society of Hematology

Evaluation of Hematologic Endpoints Used To Assess Erythropoiesis-Stimulating Agents (ESAs): A Pooled Analysis of Data from over 10,000 Patients (pts) with Chemotherapy-Induced Anemia (CIA).

A Phase 2, Randomized, Open-Label Study To Assess the Efficacy of Extended Dose Schedule Administration of Darbepoetin Alfa (DA) in Cancer Patients (pts) with Chemotherapy-Induced Anemia (CIA).

Treating Anemia of Cancer with Darbepoetin Alfa Administered Every 4 Weeks: Final Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study in Cancer Patients Not Receiving Chemotherapy and/or Radiotherapy.

Effect of Dose Reductions on Response to 500-μg Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.

Effects of Dose Adjustment Rules on Safety during Erythropoietic Therapy: A Retrospective Analysis of Darbepoetin alfa Administered Either Every 3 Weeks or Weekly.

Impact of Darbepoetin Alfa on Transfusion, Hemoglobin Response, and Survival in Cancer Patients with Chemotherapy-Induced Anemia: Results of a Meta-Analysis of Randomized, Placebo-Controlled Trials.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only